|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
CDB-4124
|
MedKoo Code#:
200680
|
|
Name:
CDB-4124
|
|
CAS#:
136960-00-4
Synonym: CDB-4124;
Proellex™； Progenta™;
17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione.。
IUPAC/Chemical name:
17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione.
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Chemical Formula: C31H39NO5
Exact Mass: 505.28282
Molecular Weight: 505.64
m/z: 505.28282 (100.0%), 506.28618 (33.5%),
507.28953 (5.4%), 507.28707 (1.0%)
Elemental Analysis: C, 73.63; H, 7.77; N,
2.77; O, 15.82
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
CDB-4124 (proposed trade names Proellex, Progenta)
is an investigational selective progesterone receptor modulator, tested
for treatment of progesterone sensitive myomata. As of September 2008,
it is undergoing Phase II and III clinical trials.
Current developer:
Repros Therapeutics
Inc
1: Spitz IM. Clinical utility of progesterone
receptor modulators and their effect on the endometrium. Curr Opin
Obstet Gynecol. 2009 Aug;21(4):318-24. Review. PubMed PMID: 19602929.
2: Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term
therapy with CDB-4124, a selective progesterone receptor modulator. Mod
Pathol. 2009 Mar;22(3):450-9. Epub 2009 Jan 9. PubMed PMID: 19136935.
3: Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor
modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin
Pharmacother. 2008 Oct;9(14):2487-96. Review. PubMed PMID: 18778186.
4: Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor
modulators 2: use in reproductive medicine. Expert Opin Pharmacother.
2008 Oct;9(14):2473-85. PubMed PMID: 18778185.
5: Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor
modulators 1: use during pregnancy. Expert Opin Pharmacother. 2008
Oct;9(14):2459-72. Review. PubMed PMID: 18778184.
6: Leo JC, Lin VC. The activities of progesterone receptor isoform A and
B are differentially modulated by their ligands in a gene-selective
manner. Int J Cancer. 2008 Jan 1;122(1):230-43. PubMed PMID: 17893877.
7: Wiehle RD, Christov K, Mehta R. Anti-progestins suppress the growth
of established tumors induced by 7,12-dimethylbenz(a)anthracene:
comparison between RU486 and a new 21-substituted-19-nor-progestin.
Oncol Rep. 2007 Jul;18(1):167-74. PubMed PMID: 17549364.
8: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2005 Apr;27(3):193-219. PubMed PMID: 15834452.
9: Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro
antiprogestational/antiglucocorticoid activity and progestin and
glucocorticoid receptor binding of the putative metabolites and
synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid
Biochem Mol Biol. 2004 Mar;88(3):277-88. PubMed PMID: 15120421.
10: Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its
putative monodemethylated metabolite, CDB-4453, are potent
antiprogestins with reduced antiglucocorticoid activity: in vitro
comparison to mifepristone and CDB-2914. Mol Cell Endocrinol. 2002 Feb
25;188(1-2):111-23. PubMed PMID: 11911951.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
